Population Health Investment Co., Inc.

Population Health Investment Co., Inc.

PHIC
Population Health Investment Co., Inc.US flagNASDAQ Capital Market
10.08
USD
+0.01
- -
No data availableFinancial data will appear here once available

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Company Description

APIChatGPT
Sector
Financial Services
Industry
Shell Companies
Address
One World Financial Center New York City NY United States of America 10281
IPO Date
Jan 8, 2021
Business
Population Health Investment Co., Inc. Population Health Investment Co., Inc. (PHIC) operates as a blank check company whose principal business activity is to effect a merger, share exchange, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or assets. The company targets opportunities in the healthcare industry, with a particular focus on the therapeutics sector, in the United States and other developed countries; it offers no current products or services beyond its special purpose acquisition structure. Incorporated in 2020 and headquartered in New York, New York, Population Health Investment Co., Inc. has not conducted significant operations or generated revenues to date. In November 2022, the company announced the redemption of all its public shares and liquidation of its trust account after failing to complete an initial business combination within the required timeframe, with shares ceasing trading on November 29, 2022, and representing only redemption rights thereafter; no subsequent mergers, acquisitions, partnerships, funding rounds, or operational restarts have been reported as of late 2025. The company maintains a lean structure led by CEO Clive Meanwell, CFO Christopher Visioli, and Chairman Ian Read, with no subsidiaries or parent relationships noted.